PepCalcs
    Back to Library

    Vesugen

    Research Use OnlyPreclinical / early clinical (Russian research). Not FDA approved.

    Vesugen

    Description

    A vascular bioregulator peptide supporting blood vessel health and circulation. Important for cardiovascular longevity.

    Dose:2 mg
    Frequency:30 days in a row, 2-3x per year
    Administration Method: SQ
    CategoryBioregulator
    Half-LifeShort (minutes); peptide bioregulators are believed to act via brief signaling pulses on gene expression.

    Overview

    Vesugen (KED) was developed at the St. Petersburg Institute of Bioregulation and Gerontology by Khavinson and colleagues. It is studied for cardiovascular and immune support, with proposed effects on endothelial function and vascular gene regulation.

    Mechanism of Action

    Synthetic tripeptide (Lys-Glu-Asp / KED) proposed to bind regulatory DNA regions and modulate gene expression in vascular endothelial and immune tissues; classified as a Khavinson short-chain bioregulator.

    Benefits

    • •Vascular health
    • •Blood flow
    • •Circulation
    • •Cardiovascular support

    Reported Side Effects

    • •Limited human safety data
    • •Possible injection site reactions

    Safety Notes

    Limited independent clinical validation outside Russian literature. Research use only.

    Scientific References

    Related Bioregulator Peptides